<DOC>
	<DOCNO>NCT00662649</DOCNO>
	<brief_summary>This extension study design evaluate long-term safety , tolerability , efficacy fingolimod ( FTY720 ) patient multiple sclerosis . The Extension study extension 24-month Core study ( CFTY720D2301/NCT00289978 ) .</brief_summary>
	<brief_title>Long-term Efficacy Safety Fingolimod ( FTY720 ) Patients With Relapsing-remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Patients complete 24 month core study Patients chronic disease immune system , malignancy , acute pulmonary disease , cardiac failure , etc . Pregnant nursing woman Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>58 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Multiple sclerosis .</keyword>
	<keyword>Relapse-remitting</keyword>
	<keyword>Fingolimod</keyword>
</DOC>